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Krooninen korkean riskin ihmisen papilloomaviruksen (HPV) aiheuttama infektio on suurin tunnettu 
riskitekijä̈ genitaali- ja suun alueen syöpien kehittymisessä. Lähes kaikki naiset saavat HPV-infektion 
elämänsä aikana ja tavanomaisesti HPV-infektio paranee spontaanisti kahden vuoden kuluessa 
aktiivisen immuunipuolustuksen avulla. Genitaali- ja suun alueen HPV-infektioiden luonnollisten 
vasta-aineiden muodostuminen ja näiden vaikutus genitaali- ja suun alueen HPV-infektion 
ilmaantuvuuteen, kestoon ja kroonistumiseen rokottamattomilla naisilla ei vielä tarkkaan tunneta.  
 
Tämän tutkimuksen tarkoituksena oli evaluoida eri HPV-vasta-ainetasojen vaikutusta genitaalien ja 
suun alueen HPV-infektioiden luonnolliseen taudinkulkuun. Tutkimuksen aineistona käytettiin Turun 
yliopissa kerättyä suomalaista perhetutkimusta (The Finnish Family HPV-study), johon osallistui 
yhteensä 329 alkutilanteessa raskaana olevaa naista, joita seurattiin yhteensä kuuden vuoden ajan. 
Tutkimuksen tilastollisissa analyyseissä huomioitiin 267 naisen ensimmäisen kolmen vuoden 
seuranta ajalta 24:n eri HPV-genotyypin aiheuttamat infektiot suun ja genitaalien alueilla. Naisten 
seerumin vasta-ainemääritykset tehtiin HPV-genotyyppien 6, 11, 16, 18 ja 45 osalta. Naisten erittäin 
korkeita sekä pysyvästi koholla olevien HPV 6, 11, 16, 18 ja 45 L1-vasta-ainetasojen vaikutusta 
tarkasteltiin saman HPV genotyypin ja minkä tahansa HPV-genotyypin aiheuttamien genitaali ja suun 
alueen HPV-infektioiden kehittymiseen.  
 
Tuloksemme osoittivat, että seurannassa naiset, jotka eivät kehittäneet lainkaan vasta-aineita HPV16-
genotyypille koko seurannan aikana ilmaantui herkemmin HPV16-genotyypin aiheuttama 
genitaalialueen infektio seurannan loppupuolella. HPV 6, 11, 18 ja 45 -genotyyppien osalta pysyvästi 
koholla olevilla vasta-ainetasoilla tai vasta-aineiden puuttumisella ei pystytty osoittamaan yhteyttä 
genitaali- tai suun alueen HPV-infektion ilmaantuvuuteen, parantumiseen tai kroonistumiseen. 
Naisten HPV-infektion kroonistumista yli 24-kuukauden ajan verrattiin HPV-infektion luonnolliseen 
parantumiseen niiden naisten keskuudessa, joilla oli erittäin korkeat joko HPV 6, 11, 16, 18 tai 45 
vasta-ainetasot verrattuna niihin, joille ei vasta-aineita kehittynyt lainkaan seurannan aikana. Edellä 
mainitussa vertailuissa korkeiden vasta-ainetasojen suhteen emme pystyneet osoittamaan 
tilastollisesti merkittävää yhteyttä minkään tutkitun HPV genotyypin osalta. Tutkimuksen 
johtopäätöksenä todettiin, että rokottamattomien nuorten naisten HPV 6, 11, 16, 18 ja 45 -
genotyyppien luonnollisesti korkeilla tai pysyvästi koholla olevilla vasta-aineinetasoilla ei näyttäisi 
olevan merkitystä genitaali- ja suun alueen HPV infektion luonnolliseen taudinkulkuun. 
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Abstract 
The role of human papillomavirus (HPV) antibodies acquired through natural infection and their 
role in protection for subsequent cervical or oral HPV remains unclear. A total of 267 women, with 
a 36-months follow-up, from the Finnish Family HPV (FFHPV) study where evaluated to shed 
more light on the role of high levels or persistence of HPV specific antibodies to the prevalence, 
persistence or clearance of genital or oral HPV infection. Women’s type-specific seroprevalence for 
HPV genotypes 6, 11, 16, 18 and 45 were evaluated for the same type-specific and any-HPV oral 
and genital HPV infections. The following different HPV serological outcomes where included: 
being always seronegative, seroconversion or persistent seropositivity. Our findings showed that 
genital HPV16 infections where more prevalent at the end of the follow-up at 24 and 36 months 
follow-up visit among women who recorded to be always seronegative for HPV16. Otherwise these 
serological outcomes did not influence the different type-specific or any-HPV genital or oral 
outcomes.  The role of high levels of antibodies for HPV 6,11,16,18 and 45 were further compared 
to those that were always seronegative to the development of long-term type-specific HPV 
6,11,16,18 and 45 persistence (≥ 24 months) or clearance of the genital and oral infections. No 
significant associations where detected among these evaluations. To conclude, among the 
unvaccinated young women investigated, we could not detect any significant role for the naturally 
acquired high or persistent level of HPV antibodies to the genital or oral HPV infections outcomes.  
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Introduction 
Most mucosal human papillomavirus (HPV) -infections are transient and clear spontaneously by 
active immunological response within a few years (1),(2),(3) . Still approximately 10-20 % of 
women fail to clear their HPV infection and are at higher risk of progressing pre-cancerous lesions. 
A persistent genital infection is known to be a key event in cervical carcinogenesis (4). HPV 
infections are closely linked not only to carcinogenesis of cervical cancer but also to the 
oropharyngeal cancer.   
 
HPV infection in both oral and genital mucosa can cause an immunological response and process of 
HPV-type-specific antibodies in the serum (5),(6). However, previous studies have shown that only 
around 50-70% of women develop in reality these antibodies after a natural infection (7),(8),(9). A 
meta-analysis concluded HPV antibodies acquired through natural infection to provide modest 
protection against subsequent cervical HPV infection among unvaccinated women (3). The 
antibody levels have shown to be also considerably lower after a natural infection compared to 
those are seen among vaccinated women (10). A mathematical model revealed that there is a large 
individual variation in the duration of HPV infection and acquired immunity, but suggested that 
naturally acquired immunity after clearance of an HPV infection may already protect part of the risk 
population against new HPV infections (11). Although, it is still unclear which is the minimum 
antibody level necessary for protection or will only higher level of naturally acquired antibody 
levels only provide protection against future HPV infections.  
 
 In this study, we investigated the women’s type specific HPV6, 11, 16, 18 and 45 antibody levels, 
especially persistent seropositivity, high antibody levels and always seronegative during the 36 
months follow-up, to the different outcomes of genital and oral HPV infections among young 
unvaccinated women.   
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Materials and methods 
 
Subjects. The Finnish Family HPV (FFHPV) study is a prospective cohort study conducted at the 
Department of Obstetrics and Gynecology, Turku University Hospital, University of Turku and at 
the Institute of Dentistry, Faculty of Medicine, University of Turku, Turku, Finland. The cohort 
group included 329 pregnant women who were recruited between 1998 and 2001 at a minimum of 
36 weeks of pregnancy and were followed up for six years after the delivery. All women are of 
Caucasian origin and have the same ethnic background. The HPV status of the women was not 
relevant at the enrolment. The HPV data of the whole FFHPV study cohort (331 mothers and 131 
fathers) has been published earlier (1)(12)(13). The Research Ethics Committee of Turku University 
and Turku University Hospital has approved the study protocol and its amendment (#2/1998 and 
#2/2006). 
Samples. Genital and oral scrapings from the women were collected for HPV-testing with a 
cytobrush (MedScand, Malmö, Sweden) as described before (12). HPV genotyping was done by 
Luminex-based Multimetrix kit (Progen Biotechnik GmbH, Heidelberg, Germany), which detects 
24 low-risk (LR)- and high-risk (HR)-HPV genotypes (LR-HPV: 6, 11, 42, 43, 44, HR-HPV: 16, 
18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, 82) (14). 
Serology. Blood samples were taken at baseline and at 12, 24 – and 36 months of the follow-up and 
stored as previously described in detail. (1) Antibodies to the major capsid protein L1 of HPV types 
6, 11, 16, 18 and 45 were analyzed by multiplex HPV serology based on glutathione S-transferase 
fusion-protein capture on fluorescent beads, as described previously (15) (16). Sera were scored as 
positive when the antigen-specific MFI values were greater than the cut-off level of 200 or 400 MFI 
(stringent) for L1 antigen of individual HPV types (17). 
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Statistical analyses. The present study focuses on the naturally acquired HPV antibody levels for 
HPV genotypes 6, 11, 16, 18 and 45 and their association to the genital and oral HPV infection 
outcomes among 267 unvaccinated women from the FFHPV study. Of the 329 women originally 
enrolled, 267 women were eligible for the present study, all having at least two serum samples 
taken during the study period. Frequency tables were analyzed using the χ2 test or the Fisher’s exact 
test for categorical variables. Differences in the means of continuous variables (i.e. log-transformed 
HPV antibody titres) were analyzed using ANOVA (analysis of variance) after controlling for their 
normal distribution. Women’s genital and oral HPV 6, 11, 16, 18 and 45 genotype specific and any-
HPV prevalence at each follow-up visit was compared with the women’s serological status for HPV 
genotypes 6, 11, 16, 18 and 45. Serological status was categorized into three groups as followed: 1) 
Always seronegative, MFI value stayed <200 with each visit;  2) Seroconversion, defined by two 
conditions: (i) an MFI value <200 in the first and >200 in the second sample, and (ii) at least a 
twofold increase of the previous serum value; and lastly 3) Persistent seropositivity, MFI value 
stayed > 200 in all follow-up visits.  The persistent and clearance of oral and genital HPV 6, 11, 16, 
18 and 45 infections where further compared between group of women with high titers of HPV 
antibody levels to those that where seronegative. High serum antibody levels were defined as 
consistently MFI >400. Persistent HPV infection was defined as being positive for type-specific 
6,11,16,18 or 45 HPV genotype for 24 months or more during the follow-up. The type-specific 
serology of HPV 6, 11, 16, 18 and 45 status where also further evaluated among the different 
clinical outcome groups of the oral and genital type-specific and any-HPV infections. Clinical 
outcome groups for oral and genital infection consisted the following: 1) Always HPV negative, 2) 
Incidence of HPV-infection, recorded when a woman who was HPV-negative at baseline acquired 
an incident HPV infection during the follow-up, 3) Clearance, women who had an event at any FU 
visit when a previously HPV-positive test turned out to be negative and remained HPV-negative 
until the end of the follow-up, 4) Persistent HPV infection, defined when HPV positivity was 
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recorded in two or more consequence visits during the follow-up. All statistical analyses were 
performed using SPSS (IBM, NY, USA, PASW Statistics version 18.0.3) and STATA13.0 (Stata 
Corp., College Station, TX, USA) software packages. All statistical tests performed were two-sided 
and declared significant at the P-value <0.05 level. 
 
Results 
The role of women’s type-specific HPV 6, 11, 16, 18 and 45 antibody levels response to these type-
specific oral and genital HPV infections was evaluated. The main aim of this study was to focus on 
serological persistence or having high level of antibody levels to those women that stayed always 
seronegative throughout the 36 months follow-up. The mean age of the women at the time of 
enrolment was 25.5 years (range 18-38) and the characteristics as the dynamics of the 
seroprevalence, seroconversion and antibody decay of these women in the FFHPV study has been 
previously described in detail (1)(13). The genotype-specific seroprevalence status of persistently 
seropositive, seroconversion or always seronegative related to the any-HPV genital infection status 
is showed in Table 1. At baseline HPV16 serology showed a significant comparison between 
always seronegative women and persistent seropositivity. Among the baseline genital any-HPV-
negative women, 134 (69.3%) where recorded always HPV16 seronegative during the follow-up 
compared to the 47 (24.4%) women recoded to be persistent HPV16 seropositive. None of the other 
follow-up visits with HPV16 or with other HPV (6, 11, 18 and 45) serology groups recorded any 
statistically significant comparisons. These same evaluations where further looked among the 
genotype specific genital infection prevalence (HPV 6, 11, 16, 18 and 45). Interestingly, among 
women that were genital HPV16 positive at 24 and 36 months visit we could detect a significant 
outcome difference between women who recorded to be always seronegative (women n range 41-
52) compared to those that recorded persistent seropositive (women n range 11-16).  With the other 
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genotype specific analysis with HPV 6, 11, 18 or 45 we could not detect any significant results 
(data not shown).  
 
These same genotype specific serological groups of persistent seropositive, seroconversion and 
always seronegative association to oral any-HPV infection status was also evaluated as shown in 
Table 2. The only statistically significant result was among HPV11 serological groups at the second 
2-months follow-up visit, 83.0 % (n=39) of any HPV-positive women were HPV11 seronegative 
compared to 6.4 % (n=3) showed seroconversion. Among HPV negative women 81.6 % (n=146) of 
were seronegative and 17. 9 % (n=32) where persistent seropositive compared to 0.6% (n=1) who 
shown seroconversion. The genotype-specific HPV assessment with 6, 11, 16, 18 or 45 oral HPV 
infection did not show any significant results with their serology (data not shown). 
 
To evaluate more the role of naturally acquired high levels of HPV specific antibody levels in 
possible protection of the infections, we evaluated women with high levels of antibody compared to 
those that recorded always HPV seronegative for the same HPV type (Table 3). We restricted there 
evaluations only to those women that recorded a ≥ 24-months type-specific persistence compared to 
those that cleared their infection (and stayed negative the rest of the follow-up). Evaluations were 
done between all HPV 6, 11, 16, 18 and 45 genotypes separately, type-specific serology to the same 
type genital or oral HPV infection outcome. We could not detect any significant results among the 
role of the antibody levels on these HPV outcomes in the genital or oral mucosa with either of the 
HPV genotype investigated.   
 
Women’s clinical outcomes for genital and oral any-HPV infections where also further also 
evaluated among the genotype specific HPV 6, 11, 16, 18 and 45 different serological groups that 
were used in Table 1 and 2 as with the two comparison groups of having high antibody levels to 
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those women that where always seronegative as in Table 3. None of these serological categories 
had significant results recorded among either in oral or genital type-specific or any-HPV outcomes 
groups of incidences, clearance, persistence or always HPV negative (data not shown).  
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Discussion 
The role of naturally acquired high HPV antibody levels compared to those women who never 
reach seroconversion are conflicting. It has been speculated that naturally acquired immunity after 
clearing an infection may already protect part of the risk population against new HPV infections 
(11). Our aim was to shed more light on this by evaluating HPV 6, 11, 16, 18 and 45 genotypes 
antibody levels and outcomes to the associations to the prevalence, persistence or clearance of 
genital and oral HPV infections.  
 
Our results showed in the genital site that being always HPV16 seronegative was associated with 
increased HPV16 genital positivity later in the follow up at 24 and 36-months compared to those 
women that were recorded to be persistence HPV16 seropositive. This is aligned with a previous 
study, where also genital HPV16 infected young women were shown to be seronegative (18). This 
association was however, only seen in the later part of the women’s follow-up why one might 
consider that these women could be later seroconverted with a longer follow-up. One possible 
explanation for this is that the HPV infection even classified as a persistent one represents a 
constantly acquired new HPV infection from the partner.  A previous study however has reported 
that there is evidence that some HPV infections do not always cause seroconversion and even 
women with persistent infection fail to seroconvert (7). Our previous results among these women 
showed that over half of the women with HPV seroconversion (67 of 134) had seroconverted to at 
least one HPV type during the follow up (1). With further evaluations in this current study with 
HPV 6,11,18 or 45 genotype serological categories with the different genital or oral outcomes no 
significant associations were detected.  
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We additionally investigated the effect of high L1-antibody levels of HPV 6, 11, 16, 18 and 45, 
compared to those that were always seronegative, to the development of long-term persistence or 
clearance of the genital and oral infections. Is has been hypothesized that high levels of natural 
antibodies would protect from acquiring subsequent HPV infections, although the true role of the 
natural antibody levels remains still undetermined (3),(19). Due to our long-term follow-up we 
could evaluate the persistence of oral and genital infection more than 24 months compared to 
women with virus clearance. Due to our restricted outcome criteria and few women in the groups, 
we could only estimate the role of high levels antibodies for HPV 16 in the oral and genital site, and 
in the genital site additionally for HPV6, however we could not detect any significant associations 
among these evaluations (Table 3). One study concluded that having high antibody levels against 
HPV16 and HPV18 following natural infection was associated with reduced risk of subsequent 
HPV16 and HPV18 infections (2). The likelihood for future protection was found  stronger with for 
high antibody levels of HPV18 than with HPV16 (2). We could not confirm this with HPV 18 due 
to low number of women among this group. Our previous findings among these women showed 
that those who cleared their cervical HPV16 infection had the highest measures of HPV16 antibody 
levels, whereas those who acquired incident HPV16 infections had the lowest antibody levels (13). 
Interesting enough, long-term persistence in the genital or oral site, however, was not predicted in 
our current analyses by being always seronegative.  
 
Protection through naturally acquired HPV L1-antibodies is likely, given that the strong antibodies 
responses to prophylactic HPV vaccination are believed to be accountable for the protection of 
future HPV infections among vaccinated women (9). Natural immunity is, though, considered to be 
inferior to the immunity acquired by HPV vaccinations in protecting against HPV reinfection (3). 
Even with smaller effect it is essential to establish whether naturally acquired antibodies protection 
is observed especially for persistent infections and precancerous lesions (2),(11). Among our 
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investigations unfortunately we could not shed more light to these questions and true nature of the 
naturally acquired antibody levels will need further investigations.  
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Table 1. Women’s serological HPV 6,11,16,18 and 45 genotype specific outcomes* and any-HPV genital prevalence at baseline, 2-, 12-, 24-, and 36- months follow-up 
visits among women of the Finnish Family HPV-study. Significant comparisons showed in bold.  
  Baseline 2 months 12 months 24 months 36 months 
HPV type Serological outcome 
HPV + 
n (%) 
HPV - 
n (%) 
HPV + 
n (%) 
HPV - 
n (%) 
HPV + 
n (%) 
HPV - 
n (%) 
HPV + 
n (%) 
HPV - 
n (%) 
HPV + 
n (%) 
HPV - 
n (%) 
 Always Seronegative 10 (24.4) 58 (31.0) 15 (38.5) 53 (28.3) 26 (23.2) 41 (36.3) 40 (32.3) 26 (30.6) 33 (29.2) 30 (34.1) 
HPV 6 Seroconversion 2 (4.9) 3 (1.6) 0 (0.0) 5 (2.7) 3 (2.7) 2 (1.8) 4 (3.2) 0 (0.0) 2 (1.8) 1 (1.1) 
 Persistent Seropositivity 29 (70.7) 126 (67.4) 24 (58.5) 129 (69.0) 83 (74.1) 70 (61.9) 80 (64.5) 59 (69.4) 78 (69.0) 57 (64.8) 
 Always Seronegative 27 (77.1) 160 (85.1) 28 (87.5) 157 (80.1) 80 (80.0) 103 (81.7) 100 (84.7) 78 (83.0) 98 (84.5) 75 (83.3) 
HPV11 Seroconversion 0 (0.0) 4 (2.1) 0 (0.0) 4 (2.0) 0 (0.0) 4 (3.2) 1 (0.8) 0 (0.0) 1 (0.9) 1 (1.1) 
 Persistent Seropositivity 8 (22.8) 31 (15.9) 4 (12.5) 35 (17.9) 20 (20.0) 19 (15.1) 17 (14.4) 16 (17.0) 17 (14.7) 14 (15.6) 
 Always Seronegative 15 (44.1) 134 (69.4) 20 (66.7) 128 (65.6) 61 (57.5) 84 (71.8) 76 (63.9) 65 (73.0) 74 (65.5) 63 (70.8) 
HPV16 Seroconversion 0 (0.0) 12 (6.2) 0 (0.0) 11 (5.6) 7 (6.6) 5 (4.3) 6 (5.0) 3 (3.4) 8 (7.1) 2 (2.2) 
 Persistent Seropositivity 19 (55.9) 47 (24.4) 10 (33.3) 56 (28.7) 38 (35.8) 28 (23.9) 37 (31.1) 21 (23.6) 31 (27.4) 24 (27.0) 
 Always Seronegative 26 (63.4) 164 (77.7) 27 (69.2) 162 (76.8) 85 (74.6) 101 (75.4) 101 (76.5) 77 (76.2) 100 (79.4) 72 (72.0) 
HPV18 Seroconversion 2 (4.9) 9 (4.3) 2 (5.1) 9 (4.3) 5 (4.4) 6 (4.5) 8 (6.1) 3 (3.0) 4 (3.2) 7 (7.0) 
 Persistent Seropositivity 13 (31.7) 38 (18.0) 10 (25.6) 40 (19.0) 24 (21.1) 27 (20.1) 23 (17.4) 21 (20.8) 22 (17.4) 21 (21.0) 
 Always Seronegative 37 (90.2) 206 (91.2) 34 (89.5) 207 (91.2) 112 (88.2) 127 (93.4) 133 (89.9) 95 (95.0) 127 (92.0) 94 (92.2) 
HPV45 Seroconversion 0 (0.0) 4 (1.8) 0 (0.0) 4 (1.8) 3 (2.4) 1 (0.7) 1 (0.7) 2 (2.0) 2 (1.4) 1 (1.0) 
 Persistent Seropositivity 4 (9.8) 16 (7.1) 4 (10.5) 16 (7.0) 12 (9.4) 8 (5.9) 14 (9.5) 3 (3.0) 9 (6.5) 7 (6.9) 
* Serological status was categorized into three groups as followed: 1) Always seronegative, MFI value stayed <200 with each visit;  2) Seroconversion, defined by two 
conditions: (i) an MFI value <200 in the first and >200 in the second sample, and (ii) at least a twofold increase of the previous serum value; and lastly 3) Persistent 
seropositivity, MFI value stayed > 200 in all follow-up visits. 
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Table 2. Women’s serological HPV 6,11,16,18 and 45 genotype specific outcomes* and any-HPV oral prevalence at baseline, 2-, 12-, 24-, and 36- months follow-up visits 
among women of the Finnish Family HPV-study. Significant comparisons showed in bold. 
  Baseline 2 months 6 months 12 months 24 months 36 months 
HPV 
type 
Serological outcome 
HPV + 
n (%) 
HPV - 
n (%) 
HPV + 
n (%) 
HPV - 
n (%) 
HPV + 
n (%) 
HPV - 
n (%) 
HPV + 
n (%) 
HPV - 
n (%) 
HPV + 
n (%) 
HPV - 
n (%) 
HPV + 
n (%) 
HPV - 
n (%) 
 Always Seronegative 12(32.4) 56 (29.6) 17(34.7) 51 (29.5) 16(30.2) 51 (30.2) 12(27.3) 56 (30.6) 14(27.5) 51 (32.7) 10(31.3) 53 (31.0) 
HPV6 Seroconversion 1 (2.7) 4 (2.1) 0 (0.0) 5 (2.9) 1 (1.9) 4 (2.4) 1 (2.3) 4 (2.2) 1 (2.0) 3 (1.9) 0 (0.0) 3 (1.8) 
 Persistent Seropositivity 24(64.9) 129 (68.3) 32 (65.3) 117 (67.6) 36 (67.9) 114 (67.5) 31 (70.5) 123 (67.2) 36 (70.6) 102 (65.4) 22 (68.8) 115 (67.3) 
 Always Seronegative 28 (80.0) 158 (81.4) 39(83.0) 146 (81.6) 46 (85.2) 137 (80.1) 33 (80.5) 153 (81.4) 42 (89.4) 137 (83.0) 26 (81.3) 148 (84.1) 
HPV11 Seroconversion 2 (5.7) 2 (1.0) 3 (6.4) 1 (0.6) 1 (1.9) 3 (1.8) 1 (2.4) 3 (1.6) 1 (2.1) 0 (0.0) 0 (0.0) 2 (1.1) 
 Persistent Seropositivity 5 (14.3) 34 (17.5) 5 (10.6) 32 (17.9) 7 (13.0) 31 (18.1) 7 (17.1) 32 (17.0) 4 (8.5) 28 (17.0) 6 (18.8) 26 (14.8) 
 Always Seronegative 26 (70.3) 122 (64.6) 30 (62.5) 116 (66.7) 28 (62.2) 117 (66.1) 24 (58.5) 124 (68.9) 26 (59.1) 115 (70.1) 19 (59.4) 118 (69.0) 
HPV16 Seroconversion 1 (2.7) 11 (5.8) 2 (4.2) 9 (5.2) 2 (4.4) 10 (5.6) 2 (4.9) 10 (5.6) 3 (6.8) 6 (3.7) 1 (3.1) 9 (5.3) 
 Persistent Seropositivity 10 (27.0) 56 (29.6) 16 (33.3) 49 (28.2) 15 (33.3) 50 (28.2) 15 (36.6) 51 (28.3) 15 (34.1) 43 (26.2) 12 (37.5) 44 (25.7) 
 Always Seronegative 33 (78.6) 155 (74.5) 42 (79.2) 144 (75.0) 46 (79.3) 140 (74.5) 33 (80.5) 156 (74.3) 41 (75.9) 137 (77.0) 29 (80.6) 144 (75.0) 
HPV18 Seroconversion 3 (7.1) 8 (3.8) 2 (3.8) 8 (4.2) 1 (1.7) 10 (5.3) 0 (0.0) 11 (5.2) 3 (5.6) 8 (4.5) 0 (0.0) 11 (5.7) 
 Persistent Seropositivity 6 (14.3) 45 (21.6) 9 (17.0) 4 (20.8) 11 (19.0) 38 (20.2) 8 (19.5) 43 (20.5) 10 (18.5) 33 (18.5) 7 (19.4) 37 (19.3) 
 Always Seronegative 42 (93.3) 199 (90.5) 53 (93.0) 184 (90.6) 58 (89.2) 181 (91.9) 47 (92.2) 195 (90.7) 55 (93.2) 173 (92.0) 35 (89.7) 187 (92.1) 
HPV45 Seroconversion 1 (2.2) 3 (1.4) 1 (1.8) 3 (1.5) 2 (3.1) 2 (1.0) 2 (3.9) 2 (0.9) 2 (3.4) 1 (0.5) 1 (2.6) 2 (1.0) 
 Persistent Seropositivity 2 (4.4) 18 (8.2) 3 (5.3) 16 (7.9) 5 (7.7) 14 (7.1) 2 (3.9) 18 (8.4) 2 (3.4) 14 (7.4) 3 (7.7) 14 (6.9) 
* Serological status was categorized into three groups as followed: 1) Always seronegative, MFI value stayed <200 with each visit;  2) Seroconversion, defined by two 
conditions: (i) an MFI value <200 in the first and >200 in the second sample, and (ii) at least a twofold increase of the previous serum value; and lastly 3) Persistent 
seropositivity, MFI value stayed > 200 in all follow-up visits. 
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Table 3. HPV genotype 6,11,16,18,45 -specific serology as predictor of 24-month persistence compared 
to those women who clearance their infection. Association was compared only between women with 
genotype specific high-level serology titers (MFI >400) and those that were always seronegative. No 
significant results were detected.  
HPV genotype Persistence ≥ 24 months (n) Clearance (n) OR* 95%CI 
Genital 
mucosa 
High-level 
serology 
Always 
seronegative 
High-level 
serology 
Always 
seronegative 
 
6 
1 1 4 1 
0.25 (0.002-
39.09) 
11 0 0 0 1 NC 
16 8 42 4 35 1.66 (0.40-8.16) 
18 0 3 1 4 NC 
45 0 3 0 5 NC 
Oral mucosa      
6 0 0 1 1 NC 
11 0 0 0 1 NC 
16 8 26 6 26 1.33 (0.34-5.35) 
18 1 1 0 3 NC 
45 0 0 0 0 NC 
*OR calculated as likelihood of a positive high-level serology titers to predict HPV persistence; NC= OR 
non-calculable 
 
